NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00403403,A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE),https://clinicaltrials.gov/study/NCT00403403,,COMPLETED,"This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously untreated extensive-stage small cell lung cancer (SCLC).",YES,Small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Chemotherapy|DRUG: Placebo,"Progression-free Survival (PFS), Duration of PFS, defined as the time from randomization to disease progression or on-study death, whichever occurred first., Randomization until progression or lost to follow-up (up to 2 years)","Overall Survival, Duration of overall survival from randomization until death or loss to follow-up, Randomization until death or lost of follow-up (up to 27 months)|Percentage of Participants With an Objective Response, Objective response was defined as a complete or partial response (per RECIST) determined by two investigator assessments conducted at least 4 weeks apart.

Complete Response (CR), Partial Response (PR), Incomplete Response (IR), Stable Disease (SD) (per RECIST):

Target Lesions Non-Target Lesions New Lesions Overall Response CR CR No CR CR IR/SD No PR PR Non-PD No PR, Randomization until progression or lost to follow-up (up to 2 years)|Number of Participants With an Objective Response, Objective response was defined as a complete or partial response (per RECIST) determined by two investigator assessments conducted at least 4 weeks apart.

Complete Response (CR), Partial Response (PR), Incomplete Response (IR), Stable Disease (SD) (per RECIST):

Target Lesions Non-Target Lesions New Lesions Overall Response CR CR No CR CR IR/SD No PR PR Non-PD No PR, Randomization until progression or lost to follow-up (up to 2 years)|Duration of Objective Response, Duration of response was defined as time from the first response date to disease progression or on-study death (i.e., death occurring any time from randomization to 30 days after the final treatment with bevacizumab/placebo). Objective response was defined as a complete or partial response (per RECIST) determined by two investigator assessments conducted at least 4 weeks apart., Randomization until progression or lost to follow-up (up to 2 years)",,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",AVF3995g,2007-03,2009-02,2009-06,2006-11-23,2011-02-25,2011-04-29,,
